Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics NASDAQ: DFTX plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said.